Hormonal contraception, thrombosis and age

Expert Opinion on Drug Safety

Volumn 13, Issue 10, 2014, Pages 1353-1360

  Lidegaard, Ojvind ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Age; Hormonal contraception; Oral contraceptives; Thrombosis; Venous thrombosis

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

AGE; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG USE; DYSMENORRHEA; FEMALE; GENETIC PREDISPOSITION; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; MENSTRUATION; MIGRAINE WITH AURA; OBESITY; OVARY POLYCYSTIC DISEASE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOSIS; TRANSDERMAL PATCH; VAGINA RING; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ADULT; CHEMICALLY INDUCED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; STROKE;

ADULT; AGE FACTORS; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYOCARDIAL INFARCTION; PROGESTINS; RISK FACTORS; STROKE; THROMBOSIS;

EID: 84907275664     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.950654     Document Type: Review

References (42)

1. Lidegaard Ø,Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen Doses: danish cohort study 2001 - 2009. BMJ 2011;343:d6423
2. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a thirdgeneration progestagen. Lancet 1995;346:1593-6
3. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82
4. World Health Organisation Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8
5. Jick H, Jick SS, Gurewich V, et al. Risk of ideopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93
6. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-8
7. Lewis MA, MacRae KD, Kühl-Habich D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-9
8. Farmer RDT, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8
9. Todd J-C, Lawrenson R, Farmer RDT, et al. Venous thromboembolic disease and combined oral contraceptives: a reanalysis of the MediPlus database. Hum Reprod 1999;14:1500-5
10. Bloemenkamp KWM, Rosendaal FR, Büller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999;159:65-70
11. Parkin L, Skegg DCG, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-4
12. Lidegaard Ø, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A five-year national case-control study. Contraception 2002;65:187-96
13. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women years of observation. Contraception 2007;75:344-54
14. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of estrogen Dose and progestagen type: results of the MEGA case-control study. BMJ 2009;339:b2921
15. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890
16. Dinger J, Assmann A, M€ohner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- And drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36:123-9
17. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;340:d2139
18. Jick SS, Hernandez RK. Risk of nonfatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;340:d2151
19. Food and Drug Adminidsration, Office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. FDA. 2011. Available from: http://www.fda. gov/downloads/Drugs/DrugSafety/ UCM277384.pdf
20. Gronich N, Lavi I, Rennert G. Higther risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011;183(18):E1319-25
21. Lidegaard ø, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990
22. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenonecontaining combined oral contraceptives: final results from the International Active surveillance Study of Women Taking Oral Contraceptives. Contraception 2014;89(4):253-63
23. Lidegaard ø, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thrombosis. Acta Obstet Gynecol Scand 2012;91:769-78
24. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 2002;81:482-90
25. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012;10:992-7
26. Van Vliet HAAM, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproteroneacetate. J Thromb Haemost 2004;2:2060-2
27. Le Moigne E, Delluc A, Tromeur C, et al. Risk of recurrent venous thromboembolism among young women after a first event while exposed to combined oral contraception versus not exposed to: a cohort study. Thromb Res 2013;132:51-5
28. Phillippe HM, Hornsby LB, Treadway S, et al. Inherited thrombophilia. J Pharm Pract 2014;27:227-33
29. Lidegaard ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66
30. Poulter NR, Chang CL, Farley TMM, WHO Collaborative Study of Cardiovascular Disease and Steriod Hormone Contraception. Effect on stroke of different progestagens in low estrogen Dose oral contraceptives. Lancet 1999;354:301-2
31. Heinemann LAJ, Lewis MA, Spitzer WO, et al. Thromboembolic stroke in young women. Contraception 1998;57:29-37
32. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women. A pooled analysis of two US studies. Stroke 1998;29:2277-84
33. Lidegaard ø, Kreiner S. Oral contraceptives and cerebral thrombosis. A five-year national case-control study. Contraception 2002;65:197-205
34. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med 1988;319:1313-17
35. Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception 1997;56:129-40
36. Poulter NR, Chang CL, Farley TMM, WHO collaborative study of cardiovascular disease and steroid hormone contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-9
37. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of lowdose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998;98:1058-63
38. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA casecontrol study. BMJ 1999;318:1579-83
39. Dunn NR, Arscott A, Thorogood M. The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case-control study. Contraception 2001;63:65-9
40. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001;161:1065-70
41. Tanis BC, van Den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93
42. Margolis KL, Adami HO, Luo J, et al. A prospective study of oral contraceptive use and risk of myocardial infarction among swedish women. Fertil Steril 2007;88:310-16